GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SinoMab BioScience Ltd (HKSE:03681) » Definitions » Operating Margin %

SinoMab BioScience (HKSE:03681) Operating Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is SinoMab BioScience Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. SinoMab BioScience's Operating Income for the six months ended in Dec. 2023 was HK$-123.65 Mil. SinoMab BioScience's Revenue for the six months ended in Dec. 2023 was HK$0.00 Mil. Therefore, SinoMab BioScience's Operating Margin % for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for SinoMab BioScience's Operating Margin % or its related term are showing as below:

HKSE:03681' s Operating Margin % Range Over the Past 10 Years
Min: -16818.75   Med: -8999.53   Max: -1180.31
Current: -16818.75


HKSE:03681's Operating Margin % is ranked worse than
93.26% of 1024 companies
in the Biotechnology industry
Industry Median: -155.555 vs HKSE:03681: -16818.75

SinoMab BioScience's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

SinoMab BioScience's Operating Income for the six months ended in Dec. 2023 was HK$-123.65 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-251.10 Mil.

Warning Sign:

SinoMab BioScience Ltd has never been profitable in the past 3 years. It lost money every year.


SinoMab BioScience Operating Margin % Historical Data

The historical data trend for SinoMab BioScience's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SinoMab BioScience Operating Margin % Chart

SinoMab BioScience Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial - - -1,180.31 - -16,818.75

SinoMab BioScience Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -706.25 - - -8,536.91 -

Competitive Comparison of SinoMab BioScience's Operating Margin %

For the Biotechnology subindustry, SinoMab BioScience's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SinoMab BioScience's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SinoMab BioScience's Operating Margin % distribution charts can be found below:

* The bar in red indicates where SinoMab BioScience's Operating Margin % falls into.



SinoMab BioScience Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

SinoMab BioScience's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-251.104 / 1.493
=-16,818.75 %

SinoMab BioScience's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-123.648 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SinoMab BioScience  (HKSE:03681) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


SinoMab BioScience Operating Margin % Related Terms

Thank you for viewing the detailed overview of SinoMab BioScience's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


SinoMab BioScience (HKSE:03681) Business Description

Traded in Other Exchanges
N/A
Address
No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Executives
Hainan Haiyao Co. Ltd. 2101 Beneficial owner
Liu Wenyi 2201 Interest of corporation controlled by you
Leung Shui On 2201 Interest of corporation controlled by you
Qiang Jing
West Biolake Holdings Limited 2101 Beneficial owner
Skytech Technology Limited 2101 Beneficial owner
China Citic Bank Co., Ltd., Haikou Branch 2106 Person having a security interest in shares
Xu Sijia 2101 Beneficial owner
Hai Kou Shi Nong Cun Xin Yong He Zuo Lian She 2106 Person having a security interest in shares
Apricot Oversea Holdings Limited 2101 Beneficial owner
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si 2101 Beneficial owner
Shang Hai Yue Yi Tou Zi Zhong Xin You Xian He Huo 2201 Interest of corporation controlled by you
Shang Hai Xing Ze Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Hai Nan Hai Yao Gu Fen You Xian Gong Si 2101 Beneficial owner

SinoMab BioScience (HKSE:03681) Headlines

No Headlines